4 Results for "

deucra

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "deucra" in MCE Product Catalog:

34
Deucravacitinib
Deucravacitinib
0 Images
34 Cited Publications
Art. -Nr.: HY-117287
CAS. Nr.: 1609392-27-9
Reinheit:  99.87%
Synonyms: BMS-986165
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
Deucravacitinib (hydrochloride)
Deucravacitinib (hydrochloride)
0 Images
Art. -Nr.: HY-117287A
CAS. Nr.: 1609392-28-0
Synonyms: BMS-986165 (hydrochloride)
Target:  

IFNAR STAT Interleukin Related JAK

Forschungsgebiete:  

Inflammation/Immunology

Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
Deucravacitinib-13C,d3
Deucravacitinib-13C,d3
0 Images
Art. -Nr.: HY-166594S
Deucravacitinib- 13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .
Deucravacitinib analog 1
Deucravacitinib analog 1
0 Images
Art. -Nr.: HY-181278
CAS. Nr.: 1609529-70-5
Target:  

Drug Derivative JAK

Forschungsgebiete:  

Inflammation/Immunology Cancer

Deucravacitinib analog 1 (compound 3), Deucravacitinib (HY-117287) derivative, is a TYK2 allosteric ligand. Deucravacitinib analog 1 binds to the JH2 domain of TYK2. Deucravacitinib analog 1 serves as a starting point for development of TYK2-targeting PROTAC degraders. Deucravacitinib analog 1 can be used for the researches of psoriasis and cancer .
Assay Types